Dr. Andtbacka Discusses Next Steps With T-VEC in Melanoma
April 14th 2018Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.
Read More
Dr. Andtbacka Discusses the Role of T-VEC in Melanoma
February 24th 2018Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.
Read More
Dr. Andtbacka on the OPTiM Results of T-VEC for Melanoma
June 30th 2017Robert Andtbacka, MD, associate professor in the Division of Surgial Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the long-term follow-up of overall survival data from the phase III OPTiM study of taglimogene laherparepvec (T-VEC) for patients with metastatic melanoma.
Read More